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A 67-year-old man was referred to us with a diagnosis of hepatic encephalopathy by porto-systemic shunt due to liver cirrhosis hepatitis C infection ( Figure 1 ).
Post admission, oral administration of lactulose and intravenous transfusion of a branced-chain amino acid (BCAA)-enriched solution were performed. However, his venous ammonia level did not decrease significantly. The encephalopathy was refractory to medical management such as lactulose. We decided to perform balloon occluded retrograde obliteration (BRTO) for portosystemic shunt occlusion to prevent hepatic encephalopathy, Vascular access was achieved using the Seldinger technique. Briefly, an 8-Fr sheath was inserted through the right jugular vein, and a 20-mm diameter balloon catheter (Selecon MP Catheter, Terumo, Tokyo, Japan) was inserted and inflated into the portosystemic shunt ( Figure 2) . A 2.2-Fr micro-catheter (Progreat, Terumo, Tokyo, Japan) was inserted through the balloon catheter and occlusion by one 22-mm diameter metal coil (IDC; Interlocking Detachable Coil, Boston Scientific, Marlbourough, MA, USA) and seventeen some size fibered metal coils (Interlock-18, Fibered IDC Occlusion System, Boston Scientific, Marlbourough, MA, USA). The most recent venous ammonia level prior to BRTO therapy was 223 µg/dL. BRTO with self-expandable coil embolization can achieve satisfactory occlusion of portosystemic shunt and immediate clinical improve ment in patients with hepatic encephalopathy. Venous ammonia level post BRTO was 80 µg/dL.
Portosystemic shunts may result in chronic portosystemic encephalopathy, a debilitating condition that may be refractory to medical management [1, 2] . Balloon-occluded retrograde transvenous obliteration (BRTO) is an interventional therapy for the treatment of gastric fundal varices developing in the course of a portosystemic shunt vessel [3, 4] . Due to shunt closure by the procedure, BRTO has also been applied to treat portosystemic encephalopathy [4] .
In the case of portosystemic encephalopathy, the key factor in pathogenesis is shunting of portal venous blood into the systemic circulation. Thus, shunt closure is a natural interventional target for relief of encephalopathy symptoms. Since its introduction, BRTO has been shown to be a suitable therapeutic option for patients with portosystemic encephalopathy due to various types of extrahepatic portosystemic shunts [5, 6] . In conclusion, refractory hepatic encephalopathy to medical management often improve by BRTO. 
